Forum Gilead geopend

1. [verwijderd] 28 maart 2020 23:07

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   Kaspersky schreef op 28 maart 2020 23:04:

   [...]
   Technisch -> naar beneden maandag op $70,00 - $71,00.
   Dinsdag wordt mogelijk $74,00 weer getest.
   
   Gilead blijft bij mij long in de portefeuille staan.
   

   Dit verwacht ik ook. Ben benieuwd naar 3 April. Wat verwacht jij, zal de koers enorm omhoog gaan?
   
2. [verwijderd] 28 maart 2020 23:15

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   Imjustabeginner schreef op 28 maart 2020 23:07:

   [...]
   
   Dit verwacht ik ook. Ben benieuwd naar 3 April. Wat verwacht jij, zal de koers enorm omhoog gaan?
   
   

   Technisch bepaald niet exact wat er gaat gebeuren; het lijkt erop dat we volgende week of de week daarop ook de $78,00 gaan testen. En dat zou best 3 april 2020 kunnen zijn: technisch is geen exacte voorspelling.
   
   Ik voorzie bijvoorbeeld een explosieve stijging maar wel binnen een periode van 2 jaar (vrij ruim). De 78,00 dollar lijkt binnenkort weer in beeld te komen.
   
   De algoritmen kunnen de koers nog 2 jaar zijwaarts laten gaan (als je dividend meerekent is het nog steeds een stijging); om daarna als iedereen eruit is geschud met grotere percentages te gaan stijgen.
3. Ralph01A 28 maart 2020 23:48

   auteur info

   • Ralph01A

     Lid sinds: 17 okt 2008

     Laatste bezoek: 19 feb 2025

   • Aanbevelingen

     Ontvangen: 11

     Gegeven: 1

   •    Aantal posts: 316

   Gilead CEO: We're on track to have initial data in the coming weeks
   
   Mar. 28, 2020 6:19 PM ET|About: Gilead Sciences, Inc. (GILD)|By: SA Eli Hoffmann, SA News Editor
   In an open letter, Gilead (NASDAQ:GILD) CEO Daniel O'Day says he expects to have initial data about the potential of remdesivir to combat coronavirus "in the coming weeks."
   
   "When the news of the coronavirus first emerged, Gilead immediately began to investigate the potential of remdesivir, a medicine we had been studying for many years as part of our extensive research in antivirals. Remdesivir had never been approved for use but based on what we had learned to date, we knew it might have potential with the novel coronavirus. Since then, we have been working with the greatest sense of urgency and responsibility to determine whether remdesivir does indeed work against COVID-19," he writes.
   
   "Multiple studies are ongoing, and we are on track to have initial data in the coming weeks. If it is approved, we will work to ensure affordability and access so that remdesivir is available to patients with the greatest need.
   
   "In the meantime, we have made the investigational medicine available for severely ill patients who cannot enroll in a trial. This 'compassionate use' program is typically reserved for a small number of individual cases but there is nothing typical about this crisis and to date we have provided remdesivir to more than 1,000 patients.
   
   "With expanded access, hospitals or physicians can apply for emergency use of remdesivir for multiple severely ill patients at a time. While it will take some time to build a network of active sites, this approach will ultimately accelerate emergency access for more people."
   
   Als gilead slechte resultaten terug zou hebben gekregen op de meer dan 1000 patienten aan wie al remdesivir al is verstrekt zouden ze dit persbericht waarschijnlijk niet zo proactief naar buiten hebben gebracht.
   
4. Ralph01A 28 maart 2020 23:50

   auteur info

   • Ralph01A

     Lid sinds: 17 okt 2008

     Laatste bezoek: 19 feb 2025

   • Aanbevelingen

     Ontvangen: 11

     Gegeven: 1

   •    Aantal posts: 316

   seekingalpha.com/article/4334581-gile...
   
   Ook goed om de kritische signalen tot je te nemen dat trials vaak tegenvallen.
5. Endless 29 maart 2020 00:05

   auteur info

   • Endless

     Lid sinds: 06 jan 2015

     Laatste bezoek: 19 feb 2025

   • Aanbevelingen

     Ontvangen: 2797

     Gegeven: 2206

   •    Aantal posts: 6.002

   Steking alpha
   Gilead CEO: We're on track to have initial data in the coming weeks
   
   Mar. 28, 2020 6:19 PM ET|About: Gilead Sciences, Inc. (GILD)|By: SA Eli Hoffmann, SA News Editor
   In an open letter, Gilead (NASDAQ:GILD) CEO Daniel O'Day says he expects to have initial data about the potential of remdesivir to combat coronavirus "in the coming weeks."
   
   "When the news of the coronavirus first emerged, Gilead immediately began to investigate the potential of remdesivir, a medicine we had been studying for many years as part of our extensive research in antivirals. Remdesivir had never been approved for use but based on what we had learned to date, we knew it might have potential with the novel coronavirus. Since then, we have been working with the greatest sense of urgency and responsibility to determine whether remdesivir does indeed work against COVID-19," he writes.
   
   "Multiple studies are ongoing, and we are on track to have initial data in the coming weeks. If it is approved, we will work to ensure affordability and access so that remdesivir is available to patients with the greatest need.
   
   "In the meantime, we have made the investigational medicine available for severely ill patients who cannot enroll in a trial. This 'compassionate use' program is typically reserved for a small number of individual cases but there is nothing typical about this crisis and to date we have provided remdesivir to more than 1,000 patients.
   
   "With expanded access, hospitals or physicians can apply for emergency use of remdesivir for multiple severely ill patients at a time. While it will take some time to build a network of active sites, this approach will ultimately accelerate emergency access for more people."
   
   Last week, Gilead dropped its orphan drug designation for remdesivir, a status granted by the FDA that would have extended monopoly rights for the drug if it came on the market.
6. [verwijderd] 29 maart 2020 00:13

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Er zijn meerdere biotech die mogelijk een medicijn hebben voor Covid 19. Het zou leuk zijn als Gilead het heeft en de productie flink kan opschalen, maar persoonlijk zou ik het niet erg vinden als andere biotechbedrijven deze prijs binnenslepen.
   Gilead heeft ook goede diversificatie; een medicijn voor Covid 19 zou bij succes wel de oorzaak kunnen zijn voor de explosieve stijgingen.
   
   Tussen nu en 2022 verwacht ik explosieve stijgingen -> opvallend zijn de extra bewegingen van de afgelopen tijd. Mogelijk om wat aandelen los te krijgen.
7. [verwijderd] 29 maart 2020 07:17

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Jansens is ook in snelvaart voor vaxin. Zijn nu uit selectie van 10 naar 1 aan het afronden
8. Ralph01A 29 maart 2020 11:32

   auteur info

   • Ralph01A

     Lid sinds: 17 okt 2008

     Laatste bezoek: 19 feb 2025

   • Aanbevelingen

     Ontvangen: 11

     Gegeven: 1

   •    Aantal posts: 316

   amp.usatoday.com/amp/2934583001?__twi...
   
   To expedite access, the company announced Saturday it had begun transitioning to a system using an "expanded access" program. This allows hospitals or physicians to apply for emergency use of remdesivir for multiple severely ill patients at a time.
   
   We are doing this before knowing whether the drug is safe and effective to treat COVID-19 because of the urgency of the situation,” a company spokeswoman said via email.
9. Bakkiekoffie 30 maart 2020 16:13

   auteur info

   • Bakkiekoffie

     Lid sinds: 12 aug 2011

     Laatste bezoek: 19 feb 2025

   • Aanbevelingen

     Ontvangen: 637

     Gegeven: 69

   •    Aantal posts: 2.027

   Voor de derde keer in korte tijd zit GLD met koers rond $79/80,-
   In de boekjes vroeger grote kans op doorbraak.
   Pat op zich ook wel bij het nieuws wat er speelt, maar dat acht ik bij de tweede bounce ook al. Wat verwachten jullie?
   
10. Endless 30 maart 2020 16:14

    auteur info

    • Endless

      Lid sinds: 06 jan 2015

      Laatste bezoek: 19 feb 2025

    • Aanbevelingen

      Ontvangen: 2797

      Gegeven: 2206

    •    Aantal posts: 6.002

    Gilead nearing finish line on Forty Seven buy
    
    Mar. 30, 2020 8:40 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W. House, SA News Editor
    Gilead Sciences (NASDAQ:GILD) announces the expiration of the HSR waiting period regarding its previously announced acquisition of Forty Seven (NASDAQ:FTSV) for ~$4.9B. The transaction should close in early April.
    
    GILD is up 3% premarket on the advancement of remdesivir for the treatment of COVID-19.
12. Bakkiekoffie 30 maart 2020 16:17

    auteur info

    • Bakkiekoffie

      Lid sinds: 12 aug 2011

      Laatste bezoek: 19 feb 2025

    • Aanbevelingen

      Ontvangen: 637

      Gegeven: 69

    •    Aantal posts: 2.027

    quote:

    Bakkiekoffie schreef op 30 maart 2020 16:13:

    Voor de derde keer in korte tijd zit GLD met koers rond $79/80,-
    In de boekjes vroeger grote kans op doorbraak.
    Pat op zich ook wel bij het nieuws wat er speelt, maar dat acht ik bij de tweede bounce ook al. Wat verwachten jullie?
    
    

    Sorry, ik zag verkeerde koers. (Teveel positief zonlicht). We zitten in de € 76,-
    Dus vraag is nog niet opportuun
13. [verwijderd] 31 maart 2020 01:52

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Kasperky , Apache corp. wat denkt u daarvan? ( vind heel weinig informatie )
14. Endless 31 maart 2020 21:49

    auteur info

    • Endless

      Lid sinds: 06 jan 2015

      Laatste bezoek: 19 feb 2025

    • Aanbevelingen

      Ontvangen: 2797

      Gegeven: 2206

    •    Aantal posts: 6.002

    Good Reason To Be Hopeful For Gilead's Remdesivir
    
    Mar. 31, 2020 2:33 PM ET|12 comments | About: Gilead Sciences, Inc. (GILD)
    Richelle Cutler-Strom
    Richelle Cutler-Strom
    Long/short equity, Growth, growth at reasonable price, short-term horizon
    
    (221 followers)
    Summary
    Gilead is testing efficacy of remdesivir against the novel coronavirus (COVID-19) in multiple international trials.
    
    Remdesivir prevented severe lung damage from MERS coronovirus infection in a mouse and monkey model.
    
    Preclinical data and an explanation for the Ebola trial failure indicate that remdesivir will be a successful treatment for COVID-19.
    
    Inevitable remdesivir licensing deals, with exclusivity until 2034, and its forthcoming marketing of a blockbuster arthritis drug, filgotinib, will increase Gilead's revenue significantly.
    
    Gilead Sciences Inc. (NASDAQ:GILD) is currently testing remdesivir in multiple human trials for efficacy against the novel coronavirus (COVID-19). Remdesivir is an adenosine nucleotide prodrug that inhibits replication in a broad range of viruses (Arenaviridae, Coronaviridae, Filoviridae, Flaviviridae, and Paramyxovirida) in vitro. Remdesivir reduced lung damage inflicted from the MERS coronavirus in mice and monkeys. The animal studies showed that optimal therapeutic efficacy requires early dosing. However, MERS patients were found to have prolonged viral replication, so remdesivir may still benefit the most severe coronavirus cases.
    
    Remdesivir failed in Ebola virus trials even though remdesivir inhibited Ebola virus replication in vitro and in a monkey study. These preclinical studies indicated that remdesivir would be effective against the Ebola virus in humans. So, what went wrong? Could disappointment be around the corner for remdesivir in the COVID-19 trials?
    
    The Ebola monkey study showed that a high remdesivir concentration (10 mg/kg) was critical for maximum suppression. The trial also indicated that too high a concentration, over consecutive days, could cause liver injury. Gilead played it safe by using a low dosage in the Ebola trial (~3 mg/kg loading dose, 1.5 mg/kg maintenance dose, assuming a 66 kg patient). Thus, the dosage may not have reached an effective concentration in all cell types. Furthermore, Ebola causes systemic intravascular coagulation, which could have restricted remdesivir circulation through organs. The stronger efficacy of the Ebola targeting antibodies could be attributed to their ability to enter the lymphatic system, circumventing the coagulated capillaries - the antibodies could reach infected cells, whereas remdesivir could not.
    
    Gilead is using the same remdesivir dosage in the COVID-19 trials as used in the Ebola trial. Fortunately, COVID-19 infected patients do not have circulatory problems. Also, COVID-19 targets the lungs, and remdesivir robustly inhibits COVID-19 replication in human airway epithelial cells in vitro. The selected trial dosage is based on the effective in vitro inhibitory concentration along with in vivo pharmacokinetics and toxicity data. Accordingly, lung epithelial cells of COVID-19 infected patients receive an effective concentration of remdesivir. Remdesivir may also be more readily incorporated into coronavirus RNA than Ebola RNA since remdesivir appears to have a higher affinity for the coronavirus polymerase than the Ebola polymerase.
    
    A blogger recently opined remdesivir's unpredictable success based on the poor performance of a similar type of drug, favipiravir. However, favipiravir has never been reported to inhibit coronavirus replication (figure 2). Moreover, many nucleoside analogues fail to inhibit virus replication because the virus’s proofreading nuclease detects and removes them. Remdesivir mostly evades proofreading by the coronavirus exoribonuclease, thus allowing incorporation and viral inhibition.
    
    Nucleoside and nucleotide analogues are tried and true antiviral drugs, making up almost half of all antivirals. Chloroquine is another antiviral that has shown promise in treating COVID-19. Unfortunately, chloroquine can have serious side effects such as vomiting, diarrhea, nausea, and headache. These side effects may be particularly hazardous in ill COVID-19 patients and is out of the question for intubated patients.
    
    RNA viruses have high mutation rates and mutations in COVID-19 surface glycoproteins could eventually make the current vaccines under development less effective. An annual vaccine version, like the flu vaccine, may be necessary. Moreover, vaccines produce less protection in the elderly. Thus, a vaccine will not make remdesivir obsolete. Remdesivir's efficacy relies on polymerase nucleotides conserved across diverse coronavirus strains. This indicates that remdesivir will be front-line therapy for today's COVID-19 and tomorrow's new coronavirus strain. Gilead's first remdesivir patent filing was in 2014, which gives Gilead exclusivity rights until 2034.
    
    The first remdesivir trial result from China has an estimated primary completion date of April 3rd. With a life-saving treatment in high demand, the analysis could be expedited. Good news could be just around the corner.
    
    Financials
    
    Gilead's revenue growth has been low, with the 12 months trailing growth at a paltry 1.2%. However, Gilead still has a reasonable P/E of 17.3 and earnings will grow markedly if Gilead receives licensing revenue from remdesivir. In addition, Gilead and Galapagos (NASDAQ:GLPG) will soon bring Filgotinib to market for treating rheumatoid arthritis. Filgotinib will compete with AbbVie's (NYSE:ABBV) Rinvoq, but Gilead is hoping its strong safety record prevents a black box warning, making filgotinib the preferred treatment. Filgotinib's approval for treating other inflammatory diseases, such as Ulcerative colitis, Crohn's disease, Psoriatic arthritis, and Ankylosing spondylitis, will soon follow. The potential worldwide sales of these indications are in the billions.
    
15. Ralph01A 31 maart 2020 23:46

    auteur info

    • Ralph01A

      Lid sinds: 17 okt 2008

      Laatste bezoek: 19 feb 2025

    • Aanbevelingen

      Ontvangen: 11

      Gegeven: 1

    •    Aantal posts: 316

    www.timesofisrael.com/israeli-doctor-...
    
    In Padua, the autoimmune medicine Tocilizumab has proven effective, but can only be used once it is established that no other viruses or bacteria are present in the patients’ bodies, he said. The hospital where he works has also seen positive results from the antiviral drug Remdesivir, he added.
    
    Een ervaring van een arts in italie.
16. Endless 1 april 2020 14:20

    auteur info

    • Endless

      Lid sinds: 06 jan 2015

      Laatste bezoek: 19 feb 2025

    • Aanbevelingen

      Ontvangen: 2797

      Gegeven: 2206

    •    Aantal posts: 6.002

    Gilead Sciences launches two remdesivir studies in UK
    
    Apr. 1, 2020 7:57 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W. House, SA News Editor
    Gilead Sciences (NASDAQ:GILD) has initiated two Phase 3 clinical trials in the UK evaluating remdesivir in moderately-to-severely ill COVID-19 patients. 15 sites will be initially involved.
17. DeZwarteRidder 1 april 2020 14:32

    auteur info

    • DeZwarteRidder

      Lid sinds: 29 jun 2012

      Laatste bezoek: 19 feb 2025

    • Aanbevelingen

      Ontvangen: 24218

      Gegeven: 10561

    •    Aantal posts: 102.119

    quote:

    Endless schreef op 1 april 2020 14:20:

    Gilead Sciences launches two remdesivir studies in UK
    
    Apr. 1, 2020 7:57 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W. House, SA News Editor
    Gilead Sciences (NASDAQ:GILD) has initiated two Phase 3 clinical trials in the UK evaluating remdesivir in moderately-to-severely ill COVID-19 patients. 15 sites will be initially involved.
    

    Gelukkig zijn er genoeg proefpersonen........
18. DeZwarteRidder 1 april 2020 14:34

    auteur info

    • DeZwarteRidder

      Lid sinds: 29 jun 2012

      Laatste bezoek: 19 feb 2025

    • Aanbevelingen

      Ontvangen: 24218

      Gegeven: 10561

    •    Aantal posts: 102.119

    quote:

    Esco schreef op 29 maart 2020 07:17:

    Jansens is ook in snelvaart voor vaxin. Zijn nu uit selectie van 10 naar 1 aan het afronden
    

    Janssen gaat hun vaccin voor de kostprijs verkopen.
19. de tuinman 1 april 2020 16:10

    auteur info

    • de tuinman

      Lid sinds: 15 dec 2009

      Laatste bezoek: 19 feb 2025

    • Aanbevelingen

      Ontvangen: 4030

      Gegeven: 2224

    •    Aantal posts: 12.839

    quote:

    DeZwarteRidder schreef op 1 april 2020 14:32:

    [...]
    Gelukkig zijn er genoeg proefpersonen........
    

    Je bedoelt...helaas, zijn er genoeg proefpersonen..
20. Ralph01A 1 april 2020 22:35

    auteur info

    • Ralph01A

      Lid sinds: 17 okt 2008

      Laatste bezoek: 19 feb 2025

    • Aanbevelingen

      Ontvangen: 11

      Gegeven: 1

    •    Aantal posts: 316

    nypost.com/2020/03/20/coronavirus-in-...
    
    Meer positieve gevallen. Hopelijk duurt het niet lang meer voor de uitkomsten van de trials bekend worden, eerste in china liep af op 3 april.
21. Ralph01A 1 april 2020 22:43

    auteur info

    • Ralph01A

      Lid sinds: 17 okt 2008

      Laatste bezoek: 19 feb 2025

    • Aanbevelingen

      Ontvangen: 11

      Gegeven: 1

    •    Aantal posts: 316

    www.acsh.org/news/2020/03/31/will-rem...
    
    Werking remdesivir als middel tegen mers (ander coronavirus) bij apen,